<div id="readability-page-1"><div>GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with The Schall Law Firm The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Galectin Therapeutics Inc. (“Galectin” or “the Company”) (NASDAQ: GALT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Galectin announced on December 19, 2025, that “the U.S. Food and Drug Administration (FDA) has provided a written response, and subsequent communications, to the Company's previously submitted Type C meeting request regarding the development program for belapectin, its investigational galectin-3 inhibitor. The FDA converted the Company's initial request for an in-person or teleconference meeting to a written response.&#34; The Company added that it would pursue a follow-up Type C meeting to resolve key aspects of its trial design. Based on this news, shares of Galectin fell by 28.9% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk5NzI1MjByMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNTEyMjk5NzI1MjByMQ"/> The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.com www.schallfirm.com View source version on businesswire.com: https://www.businesswire.com/news/home/20251229972520/en/</div></div>

Galectin治疗

Schall 律师事务所正在代表 Galectin Therapeutics Inc.（纳斯达克代码：GALT）的投资者调查潜在的证券法违规行为。此次调查的重点是该公司是否在其研究药物 belapectin 方面发表了虚假或误导性的声明，此前在 FDA 对会议请求的回应后，股价出现了显著下跌。遭受损失的投资者被鼓励参与此次调查，并可以联系该事务所以获取更多信息

GALT 投资者有机会与 Schall 律师事务所一起参与 Galectin Therapeutics Inc.的欺诈调查